Clinical Trial Update: Ertugliflozin: Cardioprotective Effects on Epicardial Fat [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 trial from Stanford examines whether ertugliflozin has cardioprotective effects on epicardial fat. The study status is completed, with no resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Cardiovascular Diseases
• Insulin Resistance
• Type 2 Diabetes Mellitus

Drugs mentioned

• Ertugliflozin (Steglatro) (ertugliflozin)

Snippet

Sponsor: Stanford University | Conditions: Cardiovascular Diseases, Atherosclerosis | EARLY_Phase 1 | Status: COMPLETED